The use of mTOR inhibitors such as everolimus has shown promising results in improving outcomes of ER+/HER2- breast cancer patients(Ellard et al., 2009; Baselga et al., 2012; Andre et al., 2014; Piccart et al., 2014). This evidence concerns the gene ERBB2 and breast carcinoma.